{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:07:11Z","timestamp":1793329631357,"version":"4.5.0"},"reference-count":305,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100007075","name":"ESMO","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ESGO","id":[{"id":"https:\/\/ror.org\/013c16d18","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1093\/annonc\/mdz062","type":"journal-article","created":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T16:02:30Z","timestamp":1550678550000},"page":"672-705","source":"Crossref","is-referenced-by-count":1026,"title":["ESMO\u2013ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease"],"prefix":"10.1016","volume":"30","author":[{"given":"N.","family":"Colombo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"du Bois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ledermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.G.","family":"McCluggage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"McNeish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Morice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Baert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Belaroussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dashora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Olbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Planchamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Querleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Baert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Belaroussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Blecharz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Bruchim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Cibula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Colombo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Concin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dashora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Devouassoux-Shisheboran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"du Bois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Ferrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Glasspool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gonz\u00e1lez-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Heinzelmann-Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Joly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.W.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Kridelka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ledermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mahner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.G.","family":"McCluggage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"McNeish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Mikami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Morice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Nicum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Olbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.M.","family":"O\u2019Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Pautier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Planchamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Pignata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Querleu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Ray-Coquard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rodolakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sehouli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Selcukbiricik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.S.P.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Timmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Tognon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"van der Velden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.O.","family":"Witteveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.G.","family":"Zeimet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdz062_bb0010","unstructured":"EUCAN Cancer Factsheets: Ovary. http:\/\/eu-cancer.iarc.fr\/EUCAN\/CancerOne.aspx? Cancer=27&Gender=2 (9 April 2018, date last accessed)."},{"issue":"2","key":"10.1093\/annonc\/mdz062_bb0015","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1093\/annonc\/mdz062_bb0020","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/path.1000","article-title":"Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer","volume":"195","author":"Piek","year":"2001","journal-title":"J Pathol"},{"issue":"5","key":"10.1093\/annonc\/mdz062_bb0025","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/PAT.0000000000000291","article-title":"The secondary M\u00fcllerian system, field effect, BRCA, and tubal fimbria: our evolving understanding of the origin of tubo-ovarian high-grade serous carcinoma and why assignment of primary site matters","volume":"47","author":"Singh","year":"2015","journal-title":"Pathology"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb0030","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/his.13248","article-title":"High-grade serous carcinoma of tubo-ovarian origin: recent developments","volume":"71","author":"Singh","year":"2017","journal-title":"Histopathology"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb0035","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/PGP.0000000000000336","article-title":"The fallopian tube origin and primary site assignment in extrauterine high-grade serous carcinoma: findings of a survey of pathologists and clinicians","volume":"36","author":"McCluggage","year":"2017","journal-title":"Int J Gynecol Pathol"},{"key":"10.1093\/annonc\/mdz062_bb0040","series-title":"WHO Classification of Tumours of Female Reproductive Organs","author":"Kurman","year":"2014"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb0045","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/PAS.0000000000000353","article-title":"Incidental nonuterine high-grade serous carcinomas arise in the fallopian tube in most cases: further evidence for the tubal origin of high-grade serous carcinomas","volume":"39","author":"Gilks","year":"2015","journal-title":"The Am J Surg Pathol"},{"issue":"4","key":"10.1093\/annonc\/mdz062_bb0050","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/PAS.0000000000000352","article-title":"Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series","volume":"39","author":"Morrison","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1093\/annonc\/mdz062_bb0055","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/PAS.0000000000000199","article-title":"Early detection of high-grade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery","volume":"38","author":"Rabban","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1093\/annonc\/mdz062_bb0060","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1111\/1471-0528.14543","article-title":"Serous tubal intraepithelial carcinomas associated with high-grade serous ovarian carcinomas: a systematic review","volume":"124","author":"Chen","year":"2017","journal-title":"BJOG"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb0065","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/his.12651","article-title":"Assessment of a new system for primary site assignment in high-grade serous carcinoma of the fallopian tube, ovary, and peritoneum","volume":"67","author":"Singh","year":"2015","journal-title":"Histopathology"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb0070","doi-asserted-by":"crossref","first-page":"1093.","DOI":"10.1038\/s41467-017-00962-1","article-title":"High grade serous ovarian carcinomas originate in the fallopian tube","volume":"8","author":"Labidi-Galy","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb0075","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/path.4230","article-title":"Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling","volume":"231","author":"Bashashati","year":"2013","journal-title":"J Pathol"},{"issue":"12","key":"10.1093\/annonc\/mdz062_bb0080","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1158\/2159-8290.CD-16-0607","article-title":"Genomics of ovarian cancer progression reveals diverse metastatic trajectories including intraepithelial metastasis to the fallopian tube","volume":"6","author":"Eckert","year":"2016","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb0085","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/path.3023","article-title":"TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma\u2013evidence supporting the clonal relationship of the two lesions","volume":"226","author":"Kuhn","year":"2012","journal-title":"J Pathol"},{"issue":"4","key":"10.1093\/annonc\/mdz062_bb0090","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/modpathol.2017.159","article-title":"Extrauterine high-grade serous carcinomas with bilateral adnexal involvement as the only two disease sites are clonal based on TP53 sequencing results: implications for biology, classification, and staging","volume":"31","author":"Singh","year":"2018","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1093\/annonc\/mdz062_bb0095","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ygyno.2015.10.022","article-title":"Primary site assignment in tubo-ovarian high-grade serous carcinoma: consensus statement on unifying practice worldwide","volume":"141","author":"Singh","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdz062_bb0100","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/modpathol.2015.77","article-title":"Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)","volume":"28","author":"McCluggage","year":"2015","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijgo.2013.10.001","article-title":"Staging classification for cancer of the ovary, fallopian tube, and peritoneum","volume":"124","author":"Prat","year":"2014","journal-title":"Int J Gynaecol Obstet"},{"issue":"6","key":"10.1093\/annonc\/mdz062_bb0110","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.bpobgyn.2015.03.006","article-title":"Ovarian, fallopian tube and peritoneal cancer staging: rationale and explanation of new FIGO staging 2013","volume":"29","author":"Prat","year":"2015","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"8","key":"10.1093\/annonc\/mdz062_bb0115","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/S1470-2045(15)00086-8","article-title":"Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial","volume":"16","author":"Oza","year":"2015","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1093\/annonc\/mdz062_bb0120","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1093\/annonc\/mdz062_bb0125","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1200\/JCO.2015.63.1408","article-title":"Bevacizumab combined with weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan in platinum-resistant recurrent ovarian cancer: analysis by chemotherapy cohort of the randomized phase III AURELIA trial","volume":"33","author":"Poveda","year":"2015","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1093\/annonc\/mdz062_bb0130","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1093\/annonc\/mdz062_bb0135","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1158\/1078-0432.CCR-12-3409","article-title":"Predictive biomarkers for bevacizumab: are we there yet?","volume":"19","author":"Maru","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1093\/annonc\/mdz062_bb0140","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/jnci\/djx066","article-title":"Tumor microvessel density as a potential predictive marker for bevacizumab benefit: GOG-0218 biomarker analyses","volume":"109","author":"Bais","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"18","key":"10.1093\/annonc\/mdz062_bb0145","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1158\/1078-0432.CCR-13-0489","article-title":"Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection","volume":"19","author":"Collinson","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1093\/annonc\/mdz062_bb0150","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1158\/1078-0432.CCR-13-3248","article-title":"The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer","volume":"20","author":"Backen","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"7353","key":"10.1093\/annonc\/mdz062_bb0155","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Bell","year":"2011","journal-title":"Nature"},{"issue":"9","key":"10.1093\/annonc\/mdz062_bb0160","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","article-title":"Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study","volume":"12","author":"Gelmon","year":"2011","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb0165","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1093\/annonc\/mdz062_bb0170","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1093\/annonc\/mdz062_bb0175","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1093\/annonc\/mdz062_bb0180","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","article-title":"Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial","volume":"15","author":"Ledermann","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdz062_bb0185","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10106","key":"10.1093\/annonc\/mdz062_bb0190","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"22","key":"10.1093\/annonc\/mdz062_bb0195","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1093\/annonc\/mdz062_bb0200","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","article-title":"Homologous recombination deficiency: exploiting the fundamental vulnerability of ovarian cancer","volume":"5","author":"Konstantinopoulos","year":"2015","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1093\/annonc\/mdz062_bb0205","first-page":"2233","article-title":"CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup","volume":"8","author":"Bowman","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1093\/annonc\/mdz062_bb0210","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1158\/1078-0432.CCR-06-2878","article-title":"Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients","volume":"13","author":"Smyth","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb0215","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ygyno.2012.02.037","article-title":"Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum","volume":"125","author":"Gershenson","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdz062_bb0220","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/IGC.0b013e31821bb8aa","article-title":"Clinical trials in recurrent ovarian cancer","volume":"21","author":"Friedlander","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"30","key":"10.1093\/annonc\/mdz062_bb0225","doi-asserted-by":"crossref","first-page":"4717","DOI":"10.2174\/1381612822666160505114326","article-title":"Evolution of chemosensitivity and resistance assays as predictors of clinical outcomes in epithelial ovarian cancer patients","volume":"22","author":"Monk","year":"2016","journal-title":"Curr Pharm Des"},{"issue":"6","key":"10.1093\/annonc\/mdz062_bb0230","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/IGC.0b013e3181dd0110","article-title":"Prognostic relevance of uncommon ovarian histology in women with stage III\/IV epithelial ovarian cancer","volume":"20","author":"Mackay","year":"2010","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb0235","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ygyno.2012.03.006","article-title":"BRCA1\/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer","volume":"125","author":"Dann","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"21","key":"10.1093\/annonc\/mdz062_bb0240","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdz062_bb0245","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1158\/1535-7163.MCT-11-0272","article-title":"BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin","volume":"10","author":"Safra","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb0250","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb0255","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1158\/0008-5472.CAN-13-2541","article-title":"Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1\/2 inhibitor sensitivity","volume":"74","author":"Bajrami","year":"2014","journal-title":"Cancer Res"},{"issue":"7553","key":"10.1093\/annonc\/mdz062_bb0260","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb0265","doi-asserted-by":"crossref","first-page":"16827.","DOI":"10.1038\/s41598-017-17119-1","article-title":"CRISPR\/Cas9-derived models of ovarian high grade serous carcinoma targeting BRCA1, PTEN and NF1, and correlation with platinum sensitivity","volume":"7","author":"Walton","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb0270","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/emm.2006.38","article-title":"Association between excision repair cross-complementation group 1 polymorphism and clinical outcome of platinum-based chemotherapy in patients with epithelial ovarian cancer","volume":"38","author":"Kang","year":"2006","journal-title":"Exp Mol Med"},{"issue":"2","key":"10.1093\/annonc\/mdz062_bb0275","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ygyno.2012.01.008","article-title":"Pre-treatment tumor expression of ERCC1 in women with advanced stage epithelial ovarian cancer is not predictive of clinical outcomes: a Gynecologic Oncology Group study","volume":"125","author":"Rubatt","year":"2012","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb0280","first-page":"393","article-title":"ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer","volume":"34","author":"Muallem","year":"2014","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1093\/annonc\/mdz062_bb0285","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/bjc.1989.132","article-title":"Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials","volume":"59","author":"Blackledge","year":"1989","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1093\/annonc\/mdz062_bb0290","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"10.1093\/annonc\/mdz062_bb0295","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/cncr.24152","article-title":"CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study","volume":"115","author":"Tian","year":"2009","journal-title":"Cancer"},{"issue":"5","key":"10.1093\/annonc\/mdz062_bb0300","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/IGC.0b013e31828f7a24","article-title":"CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer","volume":"23","author":"Chen","year":"2013","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"10.1093\/annonc\/mdz062_bb0305","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1002\/cncr.23374","article-title":"Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy","volume":"112","author":"Azad","year":"2008","journal-title":"Cancer"},{"issue":"8","key":"10.1093\/annonc\/mdz062_bb0310","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/annonc\/mdw238","article-title":"Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial","volume":"27","author":"Lindemann","year":"2016","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdz062_bb0315","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/14737140.2017.1360138","article-title":"The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review","volume":"17","author":"Scaletta","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"issue":"2","key":"10.1093\/annonc\/mdz062_bb0320","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1515\/cclm-2017-0019","article-title":"Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA","volume":"56","author":"Giannopoulou","year":"2018","journal-title":"Clin Chem Lab Med"},{"issue":"22","key":"10.1093\/annonc\/mdz062_bb0325","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1200\/JCO.2014.60.5212","article-title":"Chemotherapy response score: development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma","volume":"33","author":"B\u00f6hm","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdz062_bb0330","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/PGP.0000000000000307","article-title":"The chemotherapy response score (CRS): interobserver reproducibility in a simple and prognostically relevant system for reporting the histologic response to neoadjuvant chemotherapy in tuboovarian high-grade serous carcinoma","volume":"36","author":"Said","year":"2017","journal-title":"Int J Gynecol Pathol"},{"issue":"4","key":"10.1093\/annonc\/mdz062_bb0335","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/IGC.0000000000000945","article-title":"Prognostic role of histological tumor regression in patients receiving neoadjuvant chemotherapy for high-grade serous tubo-ovarian carcinoma","volume":"27","author":"Coghlan","year":"2017","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"10.1093\/annonc\/mdz062_bb0340","doi-asserted-by":"crossref","first-page":"e73.","DOI":"10.3802\/jgo.2017.28.e73","article-title":"External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma","volume":"28","author":"Lee","year":"2017","journal-title":"J Gynecol Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdz062_bb0345","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/his.13399","article-title":"The chemotherapy response score is a useful histological predictor of prognosis in high-grade serous carcinoma","volume":"72","author":"Singh","year":"2018","journal-title":"Histopathology"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb0350","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/PGP.0000000000000513","article-title":"Assessment of a chemotherapy response score (CRS) system for tubo-ovarian high-grade serous carcinoma (HGSC)","volume":"38","author":"Ditzel","year":"2019","journal-title":"Int J Gynecol Pathol"},{"key":"10.1093\/annonc\/mdz062_bb0355","doi-asserted-by":"crossref","unstructured":"PA Cohen, APowell, SB\u00f6hm et al Pathological chemotherapy response score predicts survival in patients with advanced ovarian cancer receiving neoadjuvant chemotherapy: systematic review and meta-analysis of individual patient data (July 11, 2018). Available at SSRN: https:\/\/ssrn.com\/abstract=3292601 (20 December 2018, date last accessed).","DOI":"10.2139\/ssrn.3292601"},{"issue":"2","key":"10.1093\/annonc\/mdz062_bb0360","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00000478-200202000-00001","article-title":"Mucinous tumors of the ovary: a clinicopathologic analysis of 75 borderline tumors (of intestinal type) and carcinomas","volume":"26","author":"Rodr\u00edguez","year":"2002","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10.1093\/annonc\/mdz062_bb0365","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1097\/00000478-200011000-00001","article-title":"Mucinous tumors of the ovary: a clinicopathologic study of 196 borderline tumors (of intestinal type) and carcinomas, including an evaluation of 11 cases with \u2018pseudomyxoma peritonei","volume":"24","author":"Lee","year":"2000","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"10.1093\/annonc\/mdz062_bb0370","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1038\/modpathol.3800366","volume":"18","author":"Chen","year":"2005","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1093\/annonc\/mdz062_bb0375","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/PGP.0b013e318289452e","article-title":"Primary ovarian mucinous adenocarcinoma of intestinal type: a clinicopathologic study of 46 cases","volume":"33","author":"Khunamornpong","year":"2014","journal-title":"Int J Gynecol Pathol"},{"issue":"2","key":"10.1093\/annonc\/mdz062_bb0380","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/PGP.0b013e3181bbbcc1","article-title":"Primary ovarian mucinous carcinoma of intestinal type: significance of pattern of invasion and immunohistochemical expression profile in a series of 31 cases","volume":"29","author":"Tabrizi","year":"2010","journal-title":"Int J Gynecol Pathol"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb0385","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/IGC.0000000000001202","article-title":"Characteristics and prognosis of stage I ovarian mucinous tumors according to expansile or infiltrative type","volume":"28","author":"Gouy","year":"2018","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb0390","first-page":"4","article-title":"Mucinous tumors of the ovary: a review","volume":"24","author":"Hart","year":"2005","journal-title":"Int J Gynecol Pathol"},{"issue":"4","key":"10.1093\/annonc\/mdz062_bb0395","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/PGP.0000000000000135","article-title":"Low-grade serous tumors of ovary","volume":"33","author":"Bell","year":"2014","journal-title":"Int J Gynecol Pathol"},{"issue":"2","key":"10.1093\/annonc\/mdz062_bb0400","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.pathol.2017.12.001","article-title":"Prognostic indicators in ovarian serous borderline tumours","volume":"50","author":"Malpica","year":"2018","journal-title":"Pathology"},{"issue":"6","key":"10.1093\/annonc\/mdz062_bb0405","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/PAS.0000000000000824","article-title":"Long-term behavior of serous borderline tumors subdivided into atypical proliferative tumors and noninvasive low-grade carcinomas: a population-based clinicopathologic study of 942 cases","volume":"41","author":"Vang","year":"2017","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1093\/annonc\/mdz062_bb0410","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00428-016-2040-8","article-title":"Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria","volume":"470","author":"Hauptmann","year":"2017","journal-title":"Virchows Arch"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb0415","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ygyno.2016.05.005","article-title":"Relapse and disease specific survival in 1143 Danish women diagnosed with borderline ovarian tumours (BOT)","volume":"142","author":"Karlsen","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdz062_bb0420","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/j.ejca.2013.01.035","article-title":"Borderline tumours of the ovary: a cohort study of the Arbeitsgmeinschaft Gyn\u00e4kologische Onkologie (AGO) Study Group","volume":"49","author":"du Bois","year":"2013","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb0425","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/annonc\/mdt430","article-title":"Prognostic factors for recurrence after conservative treatment in a series of 119 patients with stage I serous borderline tumors of the ovary","volume":"25","author":"Uzan","year":"2014","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdz062_bb0430","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.pathol.2017.10.006","article-title":"Endometriosis-associated ovarian neoplasia","volume":"50","author":"Matias-Guiu","year":"2018","journal-title":"Pathology"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2013.04.013","article-title":"Staging laparoscopy for the management of early-stage ovarian cancer: a metaanalysis","volume":"209","author":"Park","year":"2013","journal-title":"Am J Obstet Gynecol"},{"issue":"9251","key":"10.1093\/annonc\/mdz062_bb0440","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0140-6736(00)03590-X","article-title":"Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma","volume":"357","author":"Vergote","year":"2001","journal-title":"Lancet"},{"issue":"2","key":"10.1093\/annonc\/mdz062_bb0445","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S1072-7515(03)00234-5","article-title":"Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications","volume":"197","author":"Morice","year":"2003","journal-title":"J Am Coll Surg"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb0450","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ygyno.2011.05.001","article-title":"Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging","volume":"122","author":"Powless","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdz062_bb0455","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.gore.2017.08.006","article-title":"Staging surgery in early-stage ovarian mucinous tumors according to expansile and infiltrative types","volume":"22","author":"Gouy","year":"2017","journal-title":"Gynecol Oncol Rep"},{"issue":"7","key":"10.1093\/annonc\/mdz062_bb0460","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.ejca.2012.12.004","article-title":"Primary invasive mucinous ovarian carcinoma of the intestinal type: importance of the expansile versus infiltrative type in predicting recurrence and lymph node metastases","volume":"49","author":"Muyldermans","year":"2013","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1093\/annonc\/mdz062_bb0465","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1245\/s10434-017-5919-y","article-title":"Patterns of lymph node metastases in apparent stage I low-grade epithelial ovarian cancer: a multicenter study","volume":"24","author":"Minig","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1093\/annonc\/mdz062_bb0470","first-page":"839","article-title":"Borderline tumors of the ovary: correlation of frozen and permanent histopathologic diagnosis","volume":"95","author":"Houck","year":"2000","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb0475","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ygyno.2011.08.013","article-title":"Accuracy of frozen section diagnosis of ovarian borderline tumor","volume":"123","author":"Shih","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"11","key":"10.1093\/annonc\/mdz062_bb0480","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1093\/annonc\/mdw311","article-title":"Fertility-sparing surgery in epithelial ovarian cancer: a systematic review of oncological issues","volume":"27","author":"Bentivegna","year":"2016","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdz062_bb0485","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1200\/JCO.2009.24.8617","article-title":"Outcomes of fertility-sparing surgery for stage I epithelial ovarian cancer: a proposal for patient selection","volume":"28","author":"Satoh","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb0490","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/annonc\/mds241","article-title":"Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series","volume":"24","author":"Fruscio","year":"2013","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdz062_bb0495","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.fertnstert.2015.06.008","article-title":"Long-term follow-up of patients with an isolated ovarian recurrence after conservative treatment of epithelial ovarian cancer: review of the results of an international multicenter study comprising 545 patients","volume":"104","author":"Bentivegna","year":"2015","journal-title":"Fertil Steril"},{"issue":"12","key":"10.1093\/annonc\/mdz062_bb0500","first-page":"CD004706","article-title":"Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer","author":"Lawrie","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1093\/annonc\/mdz062_bb0505","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/annonc\/mdu116","article-title":"Optimal treatment of early-stage ovarian cancer","volume":"25","author":"Collinson","year":"2014","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdz062_bb0510","first-page":"125","article-title":"International Collaborative Ovarian Neoplasm Trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer","volume":"95","author":"Colombo","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 2","key":"10.1093\/annonc\/mdz062_bb0515","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1136\/ijgc-00009577-200311001-00002","article-title":"What have we learned from ICON1 and ACTION?","volume":"13","author":"Colombo","year":"2003","journal-title":"Int J Gynecol Cancer"},{"issue":"Suppl 6","key":"10.1093\/annonc\/mdz062_bb0520","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0959-8049(01)81512-4","article-title":"ACTION + ICON1: two parallel randomised phase III trials comparing adjuvant chemotherapy to no adjuvant chemotherapy following surgery in women with high risk early ovarian cancer [abstract]","volume":"37","author":"Colombo","year":"2001","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb0525","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/jog.12551","article-title":"Impact of adjuvant chemotherapy for stage I ovarian carcinoma with intraoperative tumor capsule rupture","volume":"41","author":"Shimizu","year":"2015","journal-title":"J Obstet Gynaecol Res"},{"issue":"4","key":"10.1093\/annonc\/mdz062_bb0530","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/IGC.0b013e31823fd413","article-title":"Adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: an analysis of fully staged patients","volume":"22","author":"Takada","year":"2012","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"10.1093\/annonc\/mdz062_bb0535","first-page":"1506","article-title":"Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan clear cell carcinoma study","volume":"20","author":"Takano","year":"2010","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"10.1093\/annonc\/mdz062_bb0540","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1097\/IGC.0b013e31825c7cbe","article-title":"Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: is it necessary for stage IA?","volume":"22","author":"Mizuno","year":"2012","journal-title":"Int J Gynecol Cancer"},{"issue":"12","key":"10.1093\/annonc\/mdz062_bb0545","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1093\/annonc\/mdx525","article-title":"Adjuvant chemotherapy in patients with stage I endometrioid or clear cell ovarian cancer in the platinum era: a surveillance, epidemiology, and end results cohort study, 2000-2013","volume":"28","author":"Oseledchyk","year":"2017","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdz062_bb0550","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/AOG.0000000000001404","article-title":"Utilization and outcomes of chemotherapy in women with intermediate-risk, early-stage ovarian cancer","volume":"127","author":"Chatterjee","year":"2016","journal-title":"Obstet Gynecol"},{"issue":"5","key":"10.1093\/annonc\/mdz062_bb0555","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s10147-013-0645-3","article-title":"A recurrence-predicting prognostic factor for patients with ovarian clear-cell adenocarcinoma at reproductive age","volume":"19","author":"Kajiyama","year":"2014","journal-title":"Int J Clin Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdz062_bb0560","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/00000478-200209000-00002","article-title":"Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion","volume":"26","author":"Prat","year":"2002","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1093\/annonc\/mdz062_bb0565","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.ejca.2009.12.012","article-title":"Understanding the problem of inadequately staging early ovarian cancer","volume":"46","author":"Timmers","year":"2010","journal-title":"Eur J Cancer"},{"issue":"13","key":"10.1093\/annonc\/mdz062_bb0570","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/jnci\/djq149","article-title":"Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial","volume":"102","author":"Trimbos","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1093\/annonc\/mdz062_bb0575","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/jnci\/95.2.113","article-title":"International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm Trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma","volume":"95","author":"Trimbos","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1093\/annonc\/mdz062_bb0580","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/jnci\/95.2.113","article-title":"Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant Chemotherapy In Ovarian Neoplasm Trial","volume":"95","author":"Trimbos","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"Part I","key":"10.1093\/annonc\/mdz062_bb0585","first-page":"201a","article-title":"Results of a randomized trial in 923 patients with high-risk early ovarian cancer, comparing adjuvant chemotherapy with no further treatment following surgery [abstract","volume":"20","author":"Vergote","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb0590","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.ygyno.2006.06.013","article-title":"Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study","volume":"102","author":"Bell","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb0595","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ygyno.2009.10.073","article-title":"The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study","volume":"116","author":"Chan","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdz062_bb0600","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/IGC.0b013e3181efd843","article-title":"Is there a high-risk subgroup of stage I epithelial ovarian cancer that is most likely to benefit from 6 versus 3 cycles of adjuvant chemotherapy?","volume":"20","author":"Bakkum-Gamez","year":"2010","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"10.1093\/annonc\/mdz062_bb0605","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/oxfordjournals.annonc.a059355","article-title":"Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). G.I.C.O.G.: Gruppo Interregionale Collaborativo in Ginecologia Oncologica","volume":"6","author":"Bolis","year":"1995","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb0610","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1023\/A:1008399414923","article-title":"Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument","volume":"11","author":"Trop\u00e9","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdz062_bb0615","first-page":"352a.","article-title":"Randomized trial on adjuvant carboplatin versus no treatment in stage I high risk ovarian cancer by the Nordic Ovarian Cancer Study Group (NOCOVA) [abstract]","volume":"16","author":"Trope","year":"1997","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"15","key":"10.1093\/annonc\/mdz062_bb0620","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJM199004123221501","article-title":"Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials","volume":"322","author":"Young","year":"1990","journal-title":"N Engl J Med"},{"issue":"9332","key":"10.1093\/annonc\/mdz062_bb0625","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(02)09738-6","article-title":"Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial","volume":"360","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb0630","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ygyno.2011.03.013","article-title":"A randomized phase III trial of IV carboplatin and paclitaxel x 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group study","volume":"122","author":"Mannel","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdz062_bb0635","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1200\/JCO.1989.7.4.457","article-title":"Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group study","volume":"7","author":"Omura","year":"1989","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb0640","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1006\/gyno.2002.6750","article-title":"Does the interval from primary surgery to chemotherapy influence progression-free survival in ovarian cancer?","volume":"86","author":"Flynn","year":"2002","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdz062_bb0645","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1038\/bjc.1995.539","article-title":"Long-term follow-up of patients with advanced ovarian cancer treated in randomised clinical trials","volume":"72","author":"Warwick","year":"1995","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1093\/annonc\/mdz062_bb0650","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1136\/ijgc-00009577-200409000-00008","article-title":"Prognostic importance of the time interval from surgery to chemotherapy in treatment of ovarian carcinoma","volume":"14","author":"Sorbe","year":"2004","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1093\/annonc\/mdz062_bb0655","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1200\/JCO.2005.03.065","article-title":"Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study","volume":"23","author":"Gadducci","year":"2005","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb0660","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ygyno.2006.07.045","article-title":"Is time to chemotherapy a determinant of prognosis in advanced-stage ovarian cancer?","volume":"104","author":"Aletti","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb0665","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ygyno.2006.01.035","article-title":"Influence of interval between primary surgery and chemotherapy on short-term survival of patients with advanced ovarian, tubal or peritoneal cancer","volume":"102","author":"Paulsen","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdz062_bb0670","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ejso.2006.02.013","article-title":"The interval from surgery to chemotherapy in the treatment of advanced epithelial ovarian carcinoma","volume":"32","author":"Rosa","year":"2006","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdz062_bb0675","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/sj.bjc.6604298","article-title":"Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival","volume":"98","author":"Wright","year":"2008","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb0680","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1093\/annonc\/mdv500","article-title":"Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology\/Gynecologic Oncology Group study","volume":"27","author":"Tewari","year":"2016","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb0685","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2012.07.023","article-title":"Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: analysis of prospective randomised phase III trials","volume":"49","author":"Mahner","year":"2013","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb0690","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ygyno.2016.09.015","article-title":"The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - an analysis of NRG Oncology\/Gynecologic Oncology Group trials","volume":"143","author":"Chan","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"23","key":"10.1093\/annonc\/mdz062_bb0695","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1200\/JCO.2003.02.154","article-title":"Adjuvant treatment for early ovarian cancer: a randomized phase III trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin\u2014a Gynecologic Oncology Group study","volume":"21","author":"Young","year":"2003","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdz062_bb0700","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/humupd\/dms047","article-title":"Fertility and borderline ovarian tumor: a systematic review of conservative management, risk of recurrence and alternative options","volume":"19","author":"Dara\u00ef","year":"2013","journal-title":"Hum Reprod Update"},{"issue":"10","key":"10.1093\/annonc\/mdz062_bb0705","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1200\/JCO.2001.19.10.2658","article-title":"Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study","volume":"19","author":"Zanetta","year":"2001","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdz062_bb0710","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/annonc\/mdu119","article-title":"Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome: results from a sub-analysis of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) ROBOT study","volume":"25","author":"Trillsch","year":"2014","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb0715","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1016\/S1470-2045(11)70288-1","article-title":"Borderline ovarian tumour: pathological diagnostic dilemma and risk factors for invasive or lethal recurrence","volume":"13","author":"Morice","year":"2012","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb0720","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000478929","article-title":"Staging with unilateral salpingo-oophorectomy and expert pathological review result in no recurrences in a series of 81 intestinal-type mucinous borderline ovarian tumors","volume":"83","author":"Dewilde","year":"2018","journal-title":"Gynecol Obstet Invest"},{"issue":"7","key":"10.1093\/annonc\/mdz062_bb0725","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/annonc\/mdu139","article-title":"Influence of histological subtypes on the risk of an invasive recurrence in a large series of stage I borderline ovarian tumor including 191 conservative treatments","volume":"25","author":"Uzan","year":"2014","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb0730","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/annonc\/mdp267","article-title":"Outcomes after conservative treatment of advanced-stage serous borderline tumors of the ovary","volume":"21","author":"Uzan","year":"2010","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdz062_bb0735","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1093\/humrep\/deq159","article-title":"Ultra-conservative fertility-sparing strategy for bilateral borderline ovarian tumours: an 11-year follow-up","volume":"25","author":"Palomba","year":"2010","journal-title":"Hum Reprod"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb0740","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ygyno.2016.10.041","article-title":"Is it necessary to perform routine appendectomy for mucinous ovarian neoplasms? A retrospective study and meta-analysis","volume":"144","author":"Cheng","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdz062_bb0745","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1245\/s10434-015-4784-9","article-title":"New pointers for surgical staging of borderline ovarian tumors","volume":"23","author":"Bendifallah","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdz062_bb0750","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ygyno.2010.07.034","article-title":"The role of restaging borderline ovarian tumors: single institution experience and review of the literature","volume":"119","author":"Zapardiel","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdz062_bb0755","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1634\/theoncologist.2008-0263","article-title":"Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants","volume":"14","author":"Kane","year":"2009","journal-title":"Oncologist"},{"issue":"6","key":"10.1093\/annonc\/mdz062_bb0760","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/01.pas.0000164030.82810.db","article-title":"Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or =5-year) follow-up","volume":"29","author":"Longacre","year":"2005","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb0765","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ygyno.2013.11.006","article-title":"Adjuvant platinum-based chemotherapy for borderline serous ovarian tumors with invasive implants","volume":"132","author":"Leary","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdz062_bb0770","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1634\/theoncologist.2014-0144","article-title":"A meta-analysis on the impact of platinum-based adjuvant treatment on the outcome of borderline ovarian tumors with invasive implants","volume":"20","author":"Vasconcelos","year":"2015","journal-title":"Oncologist"},{"issue":"11","key":"10.1093\/annonc\/mdz062_bb0775","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1200\/JCO.1995.13.11.2752","article-title":"Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a Gynecologic Oncology Group study","volume":"13","author":"Barnhill","year":"1995","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdz062_bb0780","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1471-0528.2002.01359.x","article-title":"Fertility results after conservative treatment of advanced stage serous borderline tumour of the ovary","volume":"109","author":"Camatte","year":"2002","journal-title":"BJOG"},{"issue":"7","key":"10.1093\/annonc\/mdz062_bb0785","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1016\/j.fertnstert.2010.04.045","article-title":"Fertility results and outcomes after pure laparoscopic management of advanced-stage serous borderline tumors of the ovary","volume":"94","author":"Kane","year":"2010","journal-title":"Fertil Steril"},{"issue":"4","key":"10.1093\/annonc\/mdz062_bb0790","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/annonc\/mdg173","article-title":"Prognostic factors for patients with advanced stage serous borderline tumours of the ovary","volume":"14","author":"Morice","year":"2003","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb0795","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ygyno.2011.08.008","article-title":"Micropapillary pattern in serous borderline ovarian tumors: does it matter?","volume":"123","author":"Park","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb0800","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/1097-0142(19920701)70:1<152::AID-CNCR2820700125>3.0.CO;2-6","article-title":"Serous borderline tumors of the ovary. A clinicopathologic, immunohistochemical, and quantitative study of 44 cases","volume":"70","author":"de Nictolis","year":"1992","journal-title":"Cancer"},{"issue":"4","key":"10.1093\/annonc\/mdz062_bb0805","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/00000478-199904000-00004","article-title":"Ovarian serous borderline tumors with micropapillary and cribriform patterns: a study of 40 cases and comparison with 44 cases without these patterns","volume":"23","author":"Eichhorn","year":"1999","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb0810","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1245\/s10434-011-2039-y","article-title":"Behavior of serous borderline ovarian tumors with and without micropapillary patterns: results of a French multicenter study","volume":"19","author":"Fauvet","year":"2012","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb0815","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/1097-0142(19900201)65:3<578::AID-CNCR2820650332>3.0.CO;2-N","article-title":"Serous ovarian tumors of low malignant potential with peritoneal implants","volume":"65","author":"Gershenson","year":"1990","journal-title":"Cancer"},{"issue":"6","key":"10.1093\/annonc\/mdz062_bb0820","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1002\/(SICI)1097-0142(19980315)82:6<1096::AID-CNCR13>3.0.CO;2-1","article-title":"Ovarian serous borderline tumors with invasive peritoneal implants","volume":"82","author":"Gershenson","year":"1998","journal-title":"Cancer"},{"issue":"10","key":"10.1093\/annonc\/mdz062_bb0825","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2157::AID-CNCR14>3.0.CO;2-D","article-title":"Serous borderline tumors of the ovary with noninvasive peritoneal implants","volume":"83","author":"Gershenson","year":"1998","journal-title":"Cancer"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb0830","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1093\/ajcp\/114.3.380","article-title":"Ovarian micropapillary serous borderline tumors. Clinicopathologic features and outcome of seven surgically staged patients","volume":"114","author":"Goldstein","year":"2000","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"10.1093\/annonc\/mdz062_bb0835","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/(SICI)1097-0142(19960715)78:2<278::AID-CNCR14>3.0.CO;2-T","article-title":"Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma","volume":"78","author":"Kennedy","year":"1996","journal-title":"Cancer"},{"issue":"11","key":"10.1093\/annonc\/mdz062_bb0840","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1097\/00000478-199611000-00004","article-title":"Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases","volume":"20","author":"Seidman","year":"1996","journal-title":"Am J Surg Pathol"},{"issue":"11","key":"10.1093\/annonc\/mdz062_bb0845","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1097\/01.pas.0000213294.81154.95","article-title":"The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent","volume":"30","author":"Silva","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1093\/annonc\/mdz062_bb0850","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/cncy.21219","article-title":"Peritoneal washing cytologic analysis of ovarian serous tumors of low malignant potential to detect peritoneal implants and predict clinical outcome","volume":"120","author":"Sneige","year":"2012","journal-title":"Cancer Cytopathol"},{"issue":"4","key":"10.1093\/annonc\/mdz062_bb0855","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/IGC.0b013e3182129842","article-title":"Fertility-sparing surgery for borderline ovarian tumors: oncologic safety and reproductive outcomes","volume":"21","author":"Song","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1093\/annonc\/mdz062_bb0860","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ejogrb.2014.12.022","article-title":"Limited efficacy of platinum-based adjuvant treatment on the outcome of borderline ovarian tumors","volume":"186","author":"Vasconcelos","year":"2015","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"6","key":"10.1093\/annonc\/mdz062_bb0865","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"du Bois","year":"2009","journal-title":"Cancer"},{"issue":"5","key":"10.1093\/annonc\/mdz062_bb0870","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis","volume":"20","author":"Bristow","year":"2002","journal-title":"J Clin Oncol"},{"issue":"32","key":"10.1093\/annonc\/mdz062_bb0875","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1200\/JCO.2016.69.7458","article-title":"How to select neoadjuvant chemotherapy or primary debulking surgery in patients with stage IIIC or IV ovarian carcinoma","volume":"34","author":"Vergote","year":"2016","journal-title":"J Clin Oncol"},{"issue":"Suppl 8","key":"10.1093\/annonc\/mdz062_bb0880","doi-asserted-by":"crossref","first-page":"viii7","DOI":"10.1093\/annonc\/mdi961","article-title":"2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)","volume":"16","author":"du Bois","year":"2005","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdz062_bb0885","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/IGC.0b013e31821b2568","article-title":"2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference","volume":"21","author":"Stuart","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"10","key":"10.1093\/annonc\/mdz062_bb0890","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"issue":"9990","key":"10.1093\/annonc\/mdz062_bb0895","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","article-title":"Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial","volume":"386","author":"Kehoe","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb0900","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ygyno.2012.09.013","article-title":"Neoadjuvant chemotherapy in advanced ovarian cancer: on what do we agree and disagree?","volume":"128","author":"Vergote","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdz062_bb0905","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2017.06.010","article-title":"Diagnostic value of whole body diffusion-weighted MRI compared to computed tomography for pre-operative assessment of patients suspected for ovarian cancer","volume":"83","author":"Michielsen","year":"2017","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1093\/annonc\/mdz062_bb0910","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ygyno.2007.11.002","article-title":"Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography\/computed tomography\u2014a prospective study","volume":"108","author":"Risum","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdz062_bb0915","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/CCO.0000000000000385","article-title":"Novel imaging techniques in gynaecological cancer","volume":"29","author":"Vandecaveye","year":"2017","journal-title":"Curr Opin Oncol"},{"issue":"28","key":"10.1093\/annonc\/mdz062_bb0920","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2016.68.6907","article-title":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline","volume":"34","author":"Wright","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdz062_bb0925","doi-asserted-by":"crossref","first-page":"28.","DOI":"10.1007\/s11912-015-0449-x","article-title":"Ultrasound in gynecological cancer: is it time for re-evaluation of its uses?","volume":"17","author":"Fischerova","year":"2015","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"10.1093\/annonc\/mdz062_bb0930","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ajog.2016.01.007","article-title":"Predicting the risk of malignancy in adnexal masses based on the simple rules from the International Ovarian Tumor Analysis Group","volume":"214","author":"Timmerman","year":"2016","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"10.1093\/annonc\/mdz062_bb0935","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.ajog.2017.07.019","article-title":"Ovarian mass-differentiating benign from malignant: the value of the International Ovarian Tumor Analysis ultrasound rules","volume":"217","author":"Abramowicz","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"10.1093\/annonc\/mdz062_bb0940","doi-asserted-by":"crossref","first-page":"171.","DOI":"10.1186\/1471-2407-9-171","article-title":"Neoadjuvant chemotherapy or primary surgery for stage III\/IV ovarian cancer: contribution of diagnostic laparoscopy","volume":"9","author":"Brun","year":"2009","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1093\/annonc\/mdz062_bb0945","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1245\/ASO.2006.08.021","article-title":"A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study","volume":"13","author":"Fagotti","year":"2006","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdz062_bb0950","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1525-1438.2005.00135.x","article-title":"Port-site metastases after open laparoscopy: a study in 173 patients with advanced ovarian carcinoma","volume":"15","author":"Vergote","year":"2005","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"10.1093\/annonc\/mdz062_bb0955","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1097\/IGC.0000000000001041","article-title":"European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery","volume":"27","author":"Querleu","year":"2017","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"10.1093\/annonc\/mdz062_bb0960","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1097\/IGC.0000000000000767","article-title":"European Society of Gynaecologic Oncology quality indicators for advanced ovarian cancer surgery","volume":"26","author":"Querleu","year":"2016","journal-title":"Int J Gynecol Cancer"},{"issue":"26","key":"10.1093\/annonc\/mdz062_bb0965","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1093\/annonc\/mdz062_bb0970","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdz062_bb0975","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ygyno.2013.04.139","article-title":"Outcome differences in patients with advanced epithelial ovarian, primary peritoneal and fallopian tube cancers with and without bevacizumab","volume":"130","author":"Randall","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"12","key":"10.1093\/annonc\/mdz062_bb0980","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1200\/JCO.2013.53.6524","article-title":"Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: a Gynecologic Oncology Group study","volume":"32","author":"Burger","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdz062_bb0985","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejca.2016.09.036","article-title":"Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: results from the ANTHALYA trial","volume":"70","author":"Rouzier","year":"2017","journal-title":"Eur J Cancer"},{"issue":"15_Suppl","key":"10.1093\/annonc\/mdz062_bb0990","doi-asserted-by":"crossref","first-page":"5508","DOI":"10.1200\/JCO.2017.35.15_suppl.5508","article-title":"Phase II randomized trial of neoadjuvant (NA) chemotherapy (CT) with or without bevacizumab (Bev) in advanced epithelial ovarian cancer (EOC) (GEICO 1205\/NOVA TRIAL","volume":"35","author":"Garcia","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdz062_bb0995","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S1470-2045(13)70363-2","article-title":"Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial","volume":"14","author":"Katsumata","year":"2013","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdz062_bb1000","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs. every-3-week paclitaxel and carboplatin for ovarian cancer","volume":"374","author":"Chan","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1093\/annonc\/mdz062_bb1005","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","article-title":"Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial","volume":"15","author":"Pignata","year":"2014","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1093\/annonc\/mdz062_bb1010","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1016\/j.ejca.2014.07.015","article-title":"Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel\/platinum induction therapy followed by standard or extended three-weekly paclitaxel\/platinum in European patients with advanced epithelial ovarian cancer","volume":"50","author":"van der Burg","year":"2014","journal-title":"Eur J Cancer"},{"issue":"Suppl 5","key":"10.1093\/annonc\/mdz062_bb1015","article-title":"ICON8: a GCIG phase III randomised trial evaluating weekly dose-dense chemotherapy integration in first-line epithelial ovarian\/fallopian tube\/primary peritoneal carcinoma (EOC) treatment: results of primary progression-free survival (PFS) analysis","volume":"28","author":"Clamp","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdz062_bb1020","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.2001.19.4.1001","volume":"19","author":"Markman","year":"2001","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1093\/annonc\/mdz062_bb1025","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1056\/NEJM199612263352603","article-title":"Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer","volume":"335","author":"Alberts","year":"1996","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb1030","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1525-1438.2006.00846.x","article-title":"A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer","volume":"17","author":"Hess","year":"2007","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb1035","first-page":"CD005340","article-title":"Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer","author":"Jaaback","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb1040","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1093\/annonc\/mdz062_bb1045","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.2014.55.9898","article-title":"Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a Gynecologic Oncology Group study","volume":"33","author":"Tewari","year":"2015","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1093\/annonc\/mdz062_bb1050","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1093\/annonc\/mdz062_bb1055","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"du Bois","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"28","key":"10.1093\/annonc\/mdz062_bb1060","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1200\/JCO.2006.06.0376","article-title":"Intraperitoneal chemotherapy in ovarian cancer remains experimental","volume":"24","author":"Gore","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb1065","first-page":"208.","article-title":"A phase III trial of bevacizumab with IV versus IP chemotherapy for ovarian, fallopian tube, and peritoneal carcinoma: an NRG oncology study","volume":"141","author":"Walker","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb1070","first-page":"74","article-title":"The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent advanced ovarian cancer: a prospective study","volume":"16","author":"Spiliotis","year":"2011","journal-title":"J BUON"},{"issue":"Suppl 3","key":"10.1093\/annonc\/mdz062_bb1075","doi-asserted-by":"crossref","first-page":"630.","DOI":"10.1245\/s10434-017-6151-5","article-title":"Comment on: surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study","volume":"24","author":"Batista","year":"2017","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdz062_bb1080","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/IGC.0000000000000864","article-title":"Brief report about the role of hyperthermic intraperitoneal chemotherapy in a prospective randomized phase 3 study in recurrent ovarian cancer from Spiliotis et al","volume":"27","author":"Harter","year":"2017","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb1085","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ygyno.2014.11.072","article-title":"A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer","volume":"136","author":"Chiva","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"15_Suppl","key":"10.1093\/annonc\/mdz062_bb1090","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.1200\/JCO.2017.35.15_suppl.5520","article-title":"Randomized trial of hyperthermic intraperitoneal chemotherapy (HIPEC) in women with primary advanced peritoneal, ovarian, and tubal cancer","volume":"35","author":"Lim","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdz062_bb1095","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/IGC.0000000000000664","article-title":"Heated intraperitoneal chemotherapy (HIPEC) for patients with recurrent ovarian cancer: a systematic literature review","volume":"26","author":"Hotouras","year":"2016","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb1100","first-page":"230","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N Engl J Med 2018"},{"issue":"5","key":"10.1093\/annonc\/mdz062_bb1105","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1245\/s10434-015-5051-9","article-title":"What should we expect after a complete cytoreduction at the time of interval or primary debulking surgery in advanced ovarian cancer?","volume":"23","author":"Chiva","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb1110","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00404-016-4080-3","article-title":"Maximal effort cytoreductive surgery for disseminated ovarian cancer in a UK setting: challenges and possibilities","volume":"294","author":"Fotopoulou","year":"2016","journal-title":"Arch Gynecol Obstet"},{"issue":"8","key":"10.1093\/annonc\/mdz062_bb1115","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1093\/annonc\/mdy198","article-title":"HIPEC: hope or hype in the fight against advanced ovarian cancer?","volume":"29","author":"Fotopoulou","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdz062_bb1120","unstructured":"I Vergote, LChiva, A.du Bois Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 2018378(14): 1362\u20131363."},{"issue":"14","key":"10.1093\/annonc\/mdz062_bb1125","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMc1802033","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"Afsar","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb1130","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ygyno.2017.11.017","article-title":"Morbidity and reversal rate of ileostomy after bowel resection during visceral-peritoneal debulking (VPD) in patients with stage IIIC-IV ovarian cancer","volume":"148","author":"Tozzi","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdz062_bb1135","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/AOG.0b013e31829ce7ec","article-title":"Survival in women with grade 1 serous ovarian carcinoma","volume":"122","author":"Fader","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb1140","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ygyno.2014.11.005","article-title":"The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer","volume":"136","author":"Crane","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb1145","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.ygyno.2011.02.017","article-title":"Low-grade serous primary peritoneal carcinoma","volume":"121","author":"Schmeler","year":"2011","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb1150","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ygyno.2007.11.013","article-title":"Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum","volume":"108","author":"Schmeler","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb1155","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ygyno.2016.01.022","article-title":"Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase","volume":"140","author":"Grabowski","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb1160","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/AOG.0000000000001867","article-title":"Outcomes of women with high-grade and low-grade advanced-stage serous epithelial ovarian cancer","volume":"129","author":"Gockley","year":"2017","journal-title":"Obstet Gynecol"},{"issue":"6","key":"10.1093\/annonc\/mdz062_bb1165","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.2004.08.078","article-title":"Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment","volume":"22","author":"Hess","year":"2004","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdz062_bb1170","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/IGC.0b013e318218f270","article-title":"Surgical and medical treatment of clear cell ovarian cancer: results from the Multicenter Italian Trials in Ovarian Cancer (MITO) 9 retrospective study","volume":"21","author":"Magazzino","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb1175","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1006\/gyno.1996.0065","article-title":"Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease","volume":"60","author":"Goff","year":"1996","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb1180","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ygyno.2017.07.127","article-title":"Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: reducing overtreatment without compromising survival?","volume":"147","author":"Fader","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdz062_bb1185","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","article-title":"Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum","volume":"35","author":"Gershenson","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdz062_bb1190","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(12)70572-7","article-title":"Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study","volume":"14","author":"Farley","year":"2013","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdz062_bb1195","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1097\/IGC.0000000000000190","article-title":"Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer","volume":"24","author":"Grisham","year":"2014","journal-title":"Int J Gynecol Cancer"},{"issue":"6","key":"10.1093\/annonc\/mdz062_bb1200","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1097\/IGC.0000000000000742","article-title":"Activity of bevacizumab in patients with low-grade serous ovarian carcinoma","volume":"26","author":"Rose","year":"2016","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb1205","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ygyno.2017.01.027","article-title":"Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: a single institution experience","volume":"145","author":"Dalton","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"34","key":"10.1093\/annonc\/mdz062_bb1210","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdz062_bb1215","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1093\/annonc\/mdz062_bb1220","first-page":"CD006119","article-title":"Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment","author":"Clarke","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1093\/annonc\/mdz062_bb1225","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/IGC.0b013e31821bb88c","article-title":"Considering early detection of relapsed ovarian cancer: a review of the literature","volume":"21","author":"Geurts","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"10.1093\/annonc\/mdz062_bb1230","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1097\/IGC.0b013e3182611451","article-title":"Impact of routine follow-up examinations on life expectancy in ovarian cancer patients: a simulation study","volume":"22","author":"Geurts","year":"2012","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1093\/annonc\/mdz062_bb1235","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/IGC.0b013e318212b87d","article-title":"No supportive evidence for clinical benefit of routine follow-up in ovarian cancer: a Dutch multicenter study","volume":"21","author":"Geurts","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"15_Suppl","key":"10.1093\/annonc\/mdz062_bb1240","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1200\/JCO.2017.35.15_suppl.5501","article-title":"Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III\/ENGOT ov20","volume":"35","author":"Du Bois","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdz062_bb1245","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ejogrb.2017.04.016","article-title":"British Gynaecological Cancer Society (BGCS) epithelial ovarian\/fallopian tube\/primary peritoneal cancer guidelines: recommendations for practice","volume":"213","author":"Fotopoulou","year":"2017","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdz062_bb1250","doi-asserted-by":"crossref","first-page":"i66","DOI":"10.1093\/annonc\/mdw080","article-title":"Patient-reported outcomes (PRO) in ovarian cancer clinical trials-lost opportunities and lessons learned","volume":"27","author":"Friedlander","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdz062_bb1255","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejca.2017.03.019","article-title":"Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer","volume":"78","author":"Joly","year":"2017","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb1260","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ejrad.2008.02.019","article-title":"CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis","volume":"71","author":"Gu","year":"2009","journal-title":"Eur J Radiol"},{"issue":"9","key":"10.1093\/annonc\/mdz062_bb1265","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1007\/s12149-016-1100-0","article-title":"Clinical usefulness of post-treatment FDG PET\/CT in patients with ovarian malignancy","volume":"30","author":"Han","year":"2016","journal-title":"Ann Nucl Med"},{"issue":"11","key":"10.1093\/annonc\/mdz062_bb1270","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1038\/bjc.2015.151","article-title":"18)F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer","volume":"112","author":"You","year":"2015","journal-title":"Br J Cancer"},{"issue":"1067","key":"10.1093\/annonc\/mdz062_bb1275","doi-asserted-by":"crossref","first-page":"20160468.","DOI":"10.1259\/bjr.20160468","article-title":"Whole-body diffusion-weighted magnetic resonance imaging in the diagnosis of recurrent ovarian cancer: a clinical feasibility study","volume":"89","author":"Michielsen","year":"2016","journal-title":"Br J Radiol"},{"issue":"4","key":"10.1093\/annonc\/mdz062_bb1280","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1007\/s00259-017-3881-3","article-title":"Comparison of (18)F-FDG PET\/MRI and MRI alone for whole-body staging and potential impact on therapeutic management of women with suspected recurrent pelvic cancer: a follow-up study","volume":"45","author":"Sawicki","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1093\/annonc\/mdz062_bb1285","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2214\/ajr.174.4.1741005","article-title":"FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features","volume":"174","author":"Berger","year":"2000","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb1290","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/IGC.0000000000000586","article-title":"Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the European Group on Tumor Markers","volume":"26","author":"S\u00f6l\u00e9tormos","year":"2016","journal-title":"Int J Gynecol Cancer"},{"issue":"9747","key":"10.1093\/annonc\/mdz062_bb1295","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(10)61268-8","article-title":"Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial","volume":"376","author":"Rustin","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"10.1093\/annonc\/mdz062_bb1300","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1089\/jwh.2014.5127","article-title":"Surveillance and care of the gynecologic cancer survivor","volume":"24","author":"Faubion","year":"2015","journal-title":"J Womens Health (Larchmt)"},{"issue":"35","key":"10.1093\/annonc\/mdz062_bb1305","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.2015.60.9719","article-title":"Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT randomized trial","volume":"33","author":"Eeles","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdz062_bb1310","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/IGC.0000000000001179","article-title":"Trial of Optimal Personalised Care after treatment-gynaecological cancer (TOPCAT-G): a randomized feasibility trial","volume":"28","author":"Morrison","year":"2018","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb1315","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/IGC.0000000000000877","article-title":"Ovarian cancer follow-up: a preliminary comparison of 2 approaches","volume":"27","author":"Lanceley","year":"2017","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1093\/annonc\/mdz062_bb1320","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3109\/02813432.2015.1118836","article-title":"General practitioners' attitudes toward follow-up after cancer treatment: a cross-sectional questionnaire study","volume":"33","author":"Fidjeland","year":"2015","journal-title":"Scand J Prim Health Care"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb1325","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2017.03.022","article-title":"An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations","volume":"146","author":"Salani","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"12","key":"10.1093\/annonc\/mdz062_bb1330","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","article-title":"Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial","volume":"13","author":"Harter","year":"2006","journal-title":"Ann Surg Oncol"},{"issue":"15_Suppl","key":"10.1093\/annonc\/mdz062_bb1335","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1200\/JCO.2018.36.15_suppl.5501","volume":"36","author":"Coleman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdz062_bb1340","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","article-title":"Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO","volume":"21","author":"Harter","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"12","key":"10.1093\/annonc\/mdz062_bb1345","first-page":"6951","article-title":"Is there a role for tertiary (TCR) and quaternary (QCR) cytoreduction in recurrent ovarian cancer?","volume":"35","author":"Fanfani","year":"2015","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1093\/annonc\/mdz062_bb1350","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1245\/s10434-012-2673-z","article-title":"Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation","volume":"20","author":"Fotopoulou","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdz062_bb1355","first-page":"CD001219","article-title":"Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer","author":"Feuer","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1093\/annonc\/mdz062_bb1360","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12957-015-0455-3","article-title":"Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer","volume":"13","author":"Peng","year":"2015","journal-title":"World J Surg Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdz062_bb1365","first-page":"CD007792","article-title":"Palliative surgery versus medical management for bowel obstruction in ovarian cancer","author":"Kucukmetin","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb1370","first-page":"CD002764","article-title":"Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer","author":"Cousins","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1093\/annonc\/mdz062_bb1375","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1097\/IGC.0b013e31829f81ca","article-title":"Salvage surgery due to bowel obstruction in advanced or relapsed ovarian cancer resulting in short bowel syndrome and long-life total parenteral nutrition: surgical and clinical outcome","volume":"23","author":"Fotopoulou","year":"2013","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"10.1093\/annonc\/mdz062_bb1380","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.ejso.2013.10.025","article-title":"Bowel obstruction in recurrent gynecologic malignancies: defining who will benefit from surgical intervention","volume":"40","author":"Perri","year":"2014","journal-title":"Eur J Surg Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdz062_bb1385","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ygyno.2004.09.058","article-title":"Percutaneous endoscopic gastrostomy tube placement in patients with malignant bowel obstruction due to ovarian carcinoma","volume":"96","author":"Pothuri","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdz062_bb1390","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ygyno.2014.06.020","article-title":"The role of palliative colorectal stents in gynaecologic malignancy","volume":"134","author":"Jutzi","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb1395","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","article-title":"Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer","volume":"139","author":"Aghajanian","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdz062_bb1400","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1093\/annonc\/mdz062_bb1405","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1200\/JCO.2013.51.4240","article-title":"Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancer","volume":"32","author":"Stockler","year":"2014","journal-title":"J Clin Oncol"},{"issue":"15_Suppl","key":"10.1093\/annonc\/mdz062_bb1410","doi-asserted-by":"crossref","first-page":"5506","DOI":"10.1200\/JCO.2018.36.15_suppl.5506","article-title":"Chemotherapy plus or minus bevacizumab for platinum-sensitive ovarian cancer patients recurring after a bevacizumab containing first line treatment: the randomized phase 3 trial MITO16B-MaNGO OV2B-ENGOT OV17","volume":"36","author":"Pignata","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdz062_bb1415","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2015.12.020","article-title":"Efficacy and safety of olaparib monotherapy in germline BRCA1\/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy","volume":"140","author":"Domchek","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1093\/annonc\/mdz062_bb1420","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ygyno.2017.08.022","article-title":"Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: integrated analysis of data from Study 10 and ARIEL2","volume":"147","author":"Oza","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1093\/annonc\/mdz062_bb1425","unstructured":"Rubraca (rucaparib). European Medicines Agency. Committee for Medicinal Products for Human Use. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/rubraca (20 December 2018, date last accessed)."},{"issue":"4","key":"10.1093\/annonc\/mdz062_bb1430","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/annonc\/mdw663","article-title":"Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease","volume":"28","author":"Wilson","year":"2017","journal-title":"Ann Oncol"},{"issue":"29","key":"10.1093\/annonc\/mdz062_bb1435","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J Clin Oncol"},{"issue":"9375","key":"10.1093\/annonc\/mdz062_bb1440","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"issue":"2","key":"10.1093\/annonc\/mdz062_bb1445","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ygyno.2015.05.042","article-title":"Phase II study of weekly paclitaxel\/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: a study in 108 patients by the Belgian Gynaecological Oncology Group","volume":"138","author":"Vergote","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"19","key":"10.1093\/annonc\/mdz062_bb1450","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1158\/1078-0432.CCR-10-0832","article-title":"Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer","volume":"16","author":"Ledermann","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"29","key":"10.1093\/annonc\/mdz062_bb1455","doi-asserted-by":"crossref","first-page":"47154","DOI":"10.18632\/oncotarget.17005","article-title":"Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1\/2 mutated patients with advanced ovarian cancer","volume":"8","author":"Rafii","year":"2017","journal-title":"Oncotarget"},{"issue":"9","key":"10.1093\/annonc\/mdz062_bb1460","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1634\/theoncologist.2017-0047","article-title":"Reducing uncertainty: predictors of stopping chemotherapy early and shortened survival time in platinum resistant\/refractory ovarian cancer\u2014the GCIG symptom benefit study","volume":"22","author":"Roncolato","year":"2017","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdz062_bb1465","first-page":"CD011129","article-title":"Early palliative care for adults with advanced cancer","volume":"6","author":"Haun","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1093\/annonc\/mdz062_bb1470","first-page":"204a","article-title":"CA125 evaluation of chemotherapy response in patients with recurrent ovarian cancer: Rustin criteria revisited","volume":"21","author":"Guastalla","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl 8","key":"10.1093\/annonc\/mdz062_bb1475","doi-asserted-by":"crossref","first-page":"viii332","DOI":"10.1093\/annonc\/mdy285.142","volume":"29","author":"Pfisterer","year":"2018","journal-title":"Ann Oncol"},{"issue":"20","key":"10.1093\/annonc\/mdz062_bb1480","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1093\/annonc\/mdz062_bb1485","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdz062_bb1490","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","article-title":"A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO\u2013MCBS)","volume":"26","author":"Cherny","year":"2015","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1093\/annonc\/mdz062_bb1495","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","article-title":"American Society of Clinical Oncology Statement: a conceptual framework to assess the value of cancer treatment options","volume":"33","author":"Schnipper","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb1500","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2017.08.012","article-title":"FDA ovarian cancer clinical trial endpoints workshop: a Society of Gynecologic Oncology White Paper","volume":"147","author":"Herzog","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"10","key":"10.1093\/annonc\/mdz062_bb1505","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-Magnitude of Clinical Benefit Scale version 1.1","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1093\/annonc\/mdz062_bb1510","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/jama.2017.21903","article-title":"Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension","volume":"319","author":"Calvert","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"10.1093\/annonc\/mdz062_bb1515","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11136-017-1729-8","article-title":"Measuring what matters MOST: validation of the measure of ovarian symptoms and treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer","volume":"27","author":"King","year":"2018","journal-title":"Qual Life Res"},{"key":"10.1093\/annonc\/mdz062_bb1520","doi-asserted-by":"crossref","first-page":"i5078.","DOI":"10.1136\/bmj.i5078","article-title":"Recommendations to improve adverse event reporting in clinical trial publications: a joint pharmaceutical industry\/journal editor perspective","volume":"355","author":"Lineberry","year":"2016","journal-title":"BMJ"},{"issue":"2","key":"10.1093\/annonc\/mdz062_bb1525","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ijrobp.2017.02.002","article-title":"Feasibility of patient reporting of symptomatic adverse events via the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) in a chemoradiotherapy cooperative group multicenter clinical trial","volume":"98","author":"Basch","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1093\/annonc\/mdz062_bb1530","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1200\/JCO.2004.06.078","article-title":"Measuring quality of life in routine oncology practice improves communication and patient well-being: a randomized controlled trial","volume":"22","author":"Velikova","year":"2004","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419311627?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419311627?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/advance-article-pdf\/doi\/10.1093\/annonc\/mdz062\/28546779\/mdz062.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/30\/5\/672\/28770896\/mdz062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T05:00:14Z","timestamp":1624683614000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419311627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":305,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["S0923753419311627"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdz062","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}